Results of Therapeutic Vaccine Trials at the AIDS Vaccine Conference

[Guest guest]

[Moderators note: The following is the highlights on the progress in Therapeutic

AIDS Vaccine Trials presented at the AIDS Vaccine Conference 2006, Amsterdam.

Aug 29 – September 1. The findings underscore the need for incorporating a

'Therapeutic AIDS Vaccine strategy' as part of Indian AIDS Vaccine research

strategy. Currently, India pursues an exclusive, HIV prevention vaccine

strategy. The opportunity cost of an exclusive prevention vaccine research

strategy would be tremendous]

Therapeutic Vaccine Trials: Chairs: Sabine Kinloch, Yves Levy

TheraVac-01: an open-label phase I study to evaluate the safety of

the HIV-1 vaccine NYVAC-B in chronic HIV-1 infected patients

successfully treated with HAART.

Pierre-andre BartCentre Hospitalier Universitaire Vaudois,

Immunology and Allergy, Lausanne, Switzerland

A phase II randomized, partially-blinded trail of antiretroviral

therapy (ART), HIV-specific Immunizations, and IL2 cycles to promote

efficient control of viral replication (ACTG A5024).

Kilby University Of Alabama At Birmingham, Birmingham, AL,

USA

Immunogenicity of the ALVAC-HIV-vCP1452 canarypox vector in HIV

infected patients = the ORVACS-Manon-02 trial.

Brigitte AutranHôpital Pitié-Salpêtrière, UPMC, INSERM U543,

Department Immunology Cellular, Paris, France

Inactivated retroviral virions with functional envelope

glycoproteins: evaluation as a therapeutic vaccine immunogen.

LifsonAIDS Vaccine Program, SAIC Frederick, Inc., National

Cancer Institute, Frederick, USA

DermaVir patch therapeutic vaccine in chronic HIV infection: from

the concept to the clinic.

nna LisziewiczGenetic Immunity KFT., Budapest, Hungary